Inhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4+ T cells ex vivo

被引:16
|
作者
Zhou, Dawei [1 ]
Hayashi, Tsuyoshi [2 ,6 ]
Jean, Maxime [2 ]
Kong, Weili [1 ,7 ]
Fiches, Guillaume [1 ]
Biswas, Ayan [1 ]
Liu, Shuai [3 ]
Yosief, Hailemichael O. [3 ]
Zhang, Xiaofeng [3 ]
Bradner, Jay [4 ]
Qi, Jun [5 ]
Zhang, Wei [3 ]
Santoso, Netty [1 ]
Zhu, Jian [1 ]
机构
[1] Ohio State Univ, Dept Pathol, Coll Med, Columbus, OH 43210 USA
[2] Univ Rochester, Dept Microbiol & Immunol, Sch Med & Dent, Rochester, NY 14642 USA
[3] Univ Massachusetts, Chem Dept, Coll Sci & Math, Boston, MA 02125 USA
[4] Novartis Inst BioMed Res, Cambridge, MA 02139 USA
[5] Harvard Med Sch, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA
[6] Natl Inst Infect Dis, Tokyo 1628640, Japan
[7] Gladstone Inst, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA
来源
SCIENCE ADVANCES | 2020年 / 6卷 / 29期
关键词
PHYSICAL INTERACTION; LATENT RESERVOIR; SURVIVAL; REACTIVATION; ACTIVATION; RESISTANCE; APOPTOSIS; TARGETS; AURORA; DEATH;
D O I
10.1126/sciadv.aba1941
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Although combination antiretroviral therapy is effective in controlling HIV-1 infection, latent HIV-1 proviruses cannot be eliminated. HIV-1 reactivation induced by the mere use of latency-reversing agents is insufficient to render death of reservoir cells, indicating that certain intrinsic survival mechanisms exist. We report that Polo-like kinase 1 (PLK1) plays a critical role in survival of CD4(+ )T cells that undergo HIV-1 reactivation from latency or de novo infection. PLK1 is elevated in both scenarios, which requires HIV-1 Nef. HIV-1 enhances PLK1 SUMOylation, causing its nuclear translocation and protein stabilization. Inhibition or knockdown of PLK1 markedly facilitates death of HIV-1-infected CD4(+) T cells. Furthermore, PLK1 inhibitors strikingly reduce the size of HIV-1 latent reservoirs in primary CD4(+) T cells. Our findings demonstrate that HIV-1 infection hijacks PLK1 to prevent cell death induced by viral cytopathic effects, and that PLK1 is a promising target for chemical "killing" of HIV-1 reservoir cells.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] SBE13 joins the family of Polo-like kinase 1 (Plk1) inhibitors
    Liu, Xiaoqi
    CELL CYCLE, 2010, 9 (03) : 445 - 446
  • [32] β-Hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1)
    Yutaka Masuda
    Ayano Nishida
    Kouichi Hori
    Takahiro Hirabayashi
    Sachiko Kajimoto
    Shigeo Nakajo
    Takeshi Kondo
    Masahiro Asaka
    Kazuyasu Nakaya
    Oncogene, 2003, 22 : 1012 - 1023
  • [33] β-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1)
    Masuda, Y
    Nishida, A
    Hori, K
    Hirabayashi, T
    Kajimoto, S
    Nakajo, S
    Kondo, T
    Asaka, M
    Nakaya, K
    ONCOGENE, 2003, 22 (07) : 1012 - 1023
  • [34] Identification of polo-like kinase 1 (PLK1) in aggressive prostate cancer by paradigm analysis
    Febbo, Phillip G.
    Goldstein, Theodore C.
    Baertsch, Robert
    Youngren, Jack
    Newton, Yulia
    Bivol, Adrian
    Small, Eric Jay
    Stuart, Joshua M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] Aromatic diacylhydrazine derivatives as a new class of polo-like kinase 1 (PLK1) inhibitors
    Sun, Juan
    Lv, Peng-Cheng
    Guo, Feng-Jiao
    Wang, Xin-Yi
    Xiao-Han
    Zhang, Yang
    Sheng, Gui-Hua
    Qian, Shao-Song
    Zhu, Hai-Liang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 81 : 420 - 426
  • [36] Combining PARP inhibition with the polo-like kinase 1 (PLK1) inhibitor onvansertib overcomes PARP inhibitor resistance
    Chiappa, Michela
    Guffanti, Federica
    Decio, Alessandra
    Aliverti, Alessandro
    Ricci, Francesca
    Scanziani, Eugenio
    Camin, Federica
    Craparotta, Ilaria
    Barbera, Maria Chiara
    Bolis, Marco
    Ridinger, Maya
    Damia, Giovanna
    CANCER RESEARCH, 2022, 82 (12)
  • [37] Inhibition of polo-like kinase 1 (PLK1) in endocrine-resistant ER plus breast cancer.
    Jansen, Valerie Malyvanh
    Bhola, Neil E.
    Bafna, Sangeeta
    Giltnane, Jennifer Margaret
    Balko, Justin M.
    Dugger, Teresa C.
    Arteaga, Carlos L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] Identification of a consensus motif for Plk (Polo-like kinase) phosphorylation reveals Myt1 as a Plk1 substrate
    Nakajima, H
    Toyoshima-Morimoto, F
    Taniguchi, E
    Nishida, E
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (28) : 25277 - 25280
  • [39] Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer
    Lashen, Ayat G.
    Toss, Michael S.
    Wootton, Louisa
    Green, Andrew R. R.
    Mongan, Nigel P.
    Madhusudan, Srinivasan
    Rakha, Emad
    HISTOPATHOLOGY, 2023, 83 (03) : 414 - 425
  • [40] Resveratrol activates DNA damage response through inhibition of polo-like kinase 1 (PLK1) in natural killer/T cell lymphoma
    Sui, Xianxian
    Zhang, Canjing
    Jiang, Yudong
    Zhou, Jianan
    Xu, Chen
    Tang, Feng
    Chen, Bobin
    Xu, Huiwen
    Wang, Songmei
    Wang, Xuanyi
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (11)